Treating COVID-19: A pharmaceutical executive’s view

McKinsey

Cedric Francois, the CEO of pharmaceutical company Apellis, discusses possible approaches to treating COVID-19 patients. Insights on Pharmaceuticals & Medical Products

A ‘GOLD standard’ in brand growth for Japan’s pharmaceutical market

McKinsey

Our GOLD standard will help transform your pharmaceutical brand and achieve accelerated growth. Asia-Pacific

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?

McKinsey

Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.

What’s behind the pharmaceutical sector’s M&A push

McKinsey

There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights

How Precision Medicine Will Transform the Pharmaceutical and Healthcare Industries

Strategy+Business

And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.

Innovating at the speed of the 21st century in pharmaceuticals

McKinsey

The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights

Healthcare innovation: Building on gains made through the crisis

McKinsey

Insights on Pharmaceuticals & Medical ProductsLeaders should consider the lessons and achievements of the COVID-19 crisis in forging new innovation aspirations—and the mechanisms needed to execute them.

Recalculating the future of drug development with quantum computing

McKinsey

Insights on Pharmaceuticals & Medical ProductsTwo experts discuss how quantum computing can help solve intractable problems in drug discovery and development.

The Pharmaceutical Industry Needs a Customer-Centric Digital Transformation - SPONSOR CONTENT FROM INDEGENE

Harvard Business

Sponsor content from Indegene. Innovation Customer service Technology Sponsor Content

Healthtech in the fast lane: What is fueling investor excitement?

McKinsey

Insights on Pharmaceuticals & Medical ProductsAs adoption of healthcare technology accelerates, it’s a good time for healthcare companies to consider investing in digital among nine potential “value pools.”.

Biopharma 2020: A landmark year and a reset for the future

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsBiopharma in 2020 has shown what it can achieve when it works at its best. How can the industry build on this renewed sense of purpose in the years ahead?

Designing an agile transformation in pharma R&D

McKinsey

Pharmaceutical companies are increasingly turning to the concept of agility to help them transform their R&D functions. Insights on Pharmaceuticals & Medical Products

Agile 87

Ten battlegrounds for digital and analytics in life sciences

McKinsey

Insights on Pharmaceuticals & Medical ProductsLife-sciences companies have yet to realize the full potential of digital and analytics. Pioneers are finding success by focusing on entire parts of the business system rather than use case projects.

System 108

How COVID-19 changes the game for biopharma in China

McKinsey

Insights on Pharmaceuticals & Medical ProductsBiopharmas should consider five areas as they deal with the crisis.

Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.

The European path to reimbursement for digital health solutions

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe “fail fast and break things” approach that tech start-ups favor probably won’t work in healthcare. A slower, more deliberate route to market and reimbursement is required.

Why tech transfer may be critical to beating COVID-19

McKinsey

Insights on Pharmaceuticals & Medical ProductsHow quickly COVID-19 vaccine production ramps up will depend on technology transfer—the capabilities and processes that can speed vaccines from development to manufacturing. Are we ready?

The Bio Revolution: Innovations transforming economies, societies, and our lives

McKinsey

Insights on Pharmaceuticals & Medical ProductsAdvances in biological science could transform economies and societies, helping to tackle global challenges from climate change to pandemics.

The biopharma marketer of the future: Closing the gap

McKinsey

Insights on Pharmaceuticals & Medical ProductsCommercial leaders share the new skills brand marketers need in the digital era to move from brand building to revenue acceleration.

Medtech’s call to action: Meeting the demand surge caused by COVID-19

McKinsey

Insights on Pharmaceuticals & Medical ProductsFive interventions have helped manufacturers ease supply constraints for medtech products during the pandemic. Important lessons have been learned along the way.

Ready for launch: Reshaping pharma’s strategy in the next normal

McKinsey & Company

As pharmaceutical companies reshape their commercial models to prepare for the uncertainties ahead, personalization and digital enablement will be crucial to launch success in the new environment. Insights on Pharmaceuticals & Medical Products

COVID-19 exposes a critical shortage of oxygen in developing countries

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe COVID-19 crisis is exacerbating what is considered a critical vulnerability in the health infrastructure of many developing countries—a severe shortage of medical oxygen.

Bioelectronics ‘jump-start’ the next wave of device therapeutics

McKinsey

Blurring the lines between pharmaceuticals and medical technology, cybermedicine has the potential to become a pillar of medical treatment and play a key role in the future of medtech innovation. Insights on Pharmaceuticals & Medical Products

COVID-19 and cell and gene therapy: How to keep innovation on track

McKinsey

Insights on Pharmaceuticals & Medical ProductsCell and gene therapies promise life-changing treatments, but the pandemic has hit the sector hard. A survey reveals the extent of the disruption and suggests actions to help companies become more resilient.

Creating value from next-generation real-world evidence

McKinsey

Insights on Pharmaceuticals & Medical ProductsLeading pharma companies are applying advanced analytics to real-world evidence generation to deliver impact at scale. How can leaders keep innovating, and what should others do to catch up?

Using ethnography to translate behavior to value in medical devices

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsMedical-device innovators need a better way to understand the unmet needs along a patient’s health journey to ensure better clinical outcomes. Ethnographic research offers a path forward.

A vision for medical affairs in 2025

McKinsey

Insights on Pharmaceuticals & Medical ProductsFour core areas of medical-affairs activity combine to maximize patient experiences and outcomes.

Responding to the demand: An interview with Vyaire Medical CEO Gaurav Agarwal

McKinsey

Insights on Pharmaceuticals & Medical Products“What I love about medical devices is this enormous capability to deliver a better way of healthcare to so many people across the world.”.

How US companies are planning for a safe return to the workplace

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn a new survey of 100 executives, respondents expect most employees to be working on-site by December. To do so, they are implementing a range of interventions that could transform how people work.

A call to action: Opportunities and challenges for CGTs in Europe

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsThe speed at which scientific breakthroughs in cell and gene therapy translate into advances in European healthcare could depend on how quickly stakeholders address some uniquely European challenges.

On pins and needles: Will COVID-19 vaccines ‘save the world’?

McKinsey

Insights on Pharmaceuticals & Medical ProductsInnovators are sprinting to develop inoculations against the novel coronavirus. Here, we summarize the latest information on research timelines and the potential impact of a vaccine on the pandemic—and society.

Improving patient adherence through data-driven insights

McKinsey

A McKinsey study points to areas pharmaceutical companies can address to combat this long-standing industry issue. Insights on Pharmaceuticals & Medical ProductsWhen patients fail to follow prescribed medical regimens, outcomes suffer.

Machine learning and therapeutics 2.0: Avoiding hype, realizing potential

McKinsey

Insights on Pharmaceuticals & Medical ProductsSix levers can help healthcare and pharma players achieve better outcomes when using machine learning.

Thermo Fisher Scientific CEO Marc Casper on provisioning the front lines in the pandemic

McKinsey

Governments, healthcare providers, and pharmaceutical companies are battling COVID-19 on different fronts. Insights on Pharmaceuticals & Medical ProductsThermo Fisher Scientific is at the nexus of all of these endeavors.

Reimagining how life sciences work will be done in the next normal

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe coronavirus pandemic has forced many changes in how life sciences work is done. It may be a misconception that this is the next normal.

White Coats, Black Scientists

Harvard Business

Race Pharmaceuticals Digital ArticleHow scientific institutions can address systemic racism.

The rise and rise of medtech in Asia

McKinsey

Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market?

Managing China’s growing oncology burden

McKinsey

Insights on Pharmaceuticals & Medical ProductsSignificant increases in incidence rates have made cancer a high priority in China. Progress has resulted from innovative treatments and greater access to care, yet much more needs to be done.

Driving the next wave of innovation in CAR T-cell therapies

McKinsey

Insights on Pharmaceuticals & Medical ProductsUnlocking the full potential of CAR T-cell therapies requires investment in four areas.

COVID-19: Overcoming supply shortages for diagnostic testing

McKinsey

Insights on Pharmaceuticals & Medical ProductsTesting is considered critical to containing COVID-19, yet many countries have encountered diagnostic-supply shortages. Understanding where constraints lie could help efforts to scale testing.